Brief: Citius Pharmaceuticals Achieves Primary And Secondary Endpoints In Phase 3 Trial Of Mino-Lok Antibiotic Lock Solution
21/05/2024 12:32
Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS ACHIEVES PRIMARY AND SECONDARY
ENDPOINTS
IN PHASE 3 TRIAL OF MINO-LOK ANTIBIOTIC LOCK SOLUTION
* TRIAL ACHIEVES STATISTICALLY SIGNIFICANT PRIMARY ENDPOINT
* TRIAL ACHIEVES STATISTICALLY SIGNIFICANT PRIMARY ENDPOINT
* MINO-LOK SHOWS STATISTICAL SIGNIFICANCE IN PHASE 3
Source text for Eikon: ID:nPn3frm9a
Further company coverage: CTXR.O
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules